|Videos|September 22, 2021

Benefits of collecting and reporting smoking status in patients with GU cancer

Author(s)Urology Times staff

"In the clinic, I think the biggest benefit, at least immediately, is that by asking and trying to figure out what a patient's tobacco use history is, you can help with quitting,” says Richard Matulewicz, MD, MS.

In this video, Richard Matulewicz, MD, MS, discusses the takeaways of the study, “Persistent deficiencies in the measurement and reporting of tobacco use in contemporary genitourinary oncology clinical trials,” presented recently at the 2021 American Urological Association Annual Meeting. Matulewicz is an assistant professor in the department of urology at Memorial Sloan Kettering Cancer Center, New York City.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Nima Almassi, MD, highlights long-term data on bladder preservation in MIBC

ByNima Almassi, MD

August 13th 2026

Alan Bryce, MD, highlights key phase 3 advances in prostate cancer

ByAlan H. Bryce, MD

August 4th 2026

Kathryn Gessner, MD, PhD, on the challenges of selecting patients for bladder preservation

ByKate Gessner, MD, PhD

July 20th 2026

Jamie Michael, MD, discusses MRI and genomics in active surveillance

ByJamie Michael, MD

July 16th 2026

Ravi Munver, MD, highlights study of first- and second-generation Aquablation systems

ByRavi Munver, MD

July 14th 2026

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent

Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery